|
| Index | - | P/E | - | EPS (ttm) | -0.18 | Insider Own | 1.00% | Shs Outstand | 104.23M | Perf Week | -7.63% |
| Market Cap | 677.26M | Forward P/E | - | EPS next Y | -0.90 | Insider Trans | 0.00% | Shs Float | 57.88M | Perf Month | -22.14% |
| Income | -17.90M | PEG | - | EPS next Q | -0.23 | Inst Own | 27.00% | Short Float | 18.83% | Perf Quarter | -5.14% |
| Sales | 4.70M | P/S | 144.10 | EPS this Y | -1.00% | Inst Trans | 0.16% | Short Ratio | 12.14 | Perf Half Y | 90.92% |
| Book/sh | 0.09 | P/B | 66.61 | EPS next Y | 1.10% | ROA | -111.40% | Target Price | - | Perf Year | 537.77% |
| Cash/sh | 0.15 | P/C | 40.80 | EPS next 5Y | - | ROE | -194.40% | 52W Range | 0.90 - 10.54 | Perf YTD | -10.66% |
| Dividend | - | P/FCF | - | EPS past 5Y | 15.20% | ROI | -124.90% | 52W High | -40.04% | Beta | 3.24 |
| Dividend % | - | Quick Ratio | 2.90 | Sales past 5Y | 16.40% | Gross Margin | 26.60% | 52W Low | 599.89% | ATR | 0.54 |
| Employees | 68 | Current Ratio | 2.90 | Sales Q/Q | 7.70% | Oper. Margin | - | RSI (14) | 42.22 | Volatility | 4.38% 7.96% |
| Optionable | Yes | Debt/Eq | 0.48 | EPS Q/Q | -67.60% | Profit Margin | - | Rel Volume | 0.34 | Prev Close | 5.99 |
| Shortable | Yes | LT Debt/Eq | 0.32 | Earnings | Mar 25 AMC | Payout | - | Avg Volume | 897.54K | Price | 6.32 |
| Recom | 1.70 | SMA20 | -8.36% | SMA50 | -15.70% | SMA200 | 24.75% | Volume | 304,199 | Change | 5.42% |
 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. It provides OVA1, Overa, and Ova1PLUS to detect the risk of ovarian malignancy. The company also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, it owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, the company is developing diagnostic algorithms; and a high-risk screening algorithm for patients who are genetically predisposed to ovarian cancer. It has entered into a collaborative research agreement with Baylor Genetics to co-develop a novel ovarian cancer early-detection test; and an agreement with Dana Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer. The company has a strategic alliance with Quest Diagnostics, Incorporated. It serves physician office and hospital laboratories, as well as physicians. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite